Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets

Out-
      side
 



 
 'B0' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'B0' found in 1 term [] and 43 definitions []
previous     26 - 30 (of 44)     next
Result Pages : [1]  [2 3 4 5 6 7 8 9]
Searchterm 'B0' was also found in the following services: 
spacer
News  (1)  Forum  (4)  
 
Magnetic Resonance SpectroscopyMRI Resource Directory:
 - Spectroscopy pool -
 
(MRS / MRSI - Magnetic Resonance Spectroscopic Imaging) A method using the NMR phenomenon to identify the chemical state of various elements without destroying the sample. MRS therefore provides information about the chemical composition of the tissues and the changes in chemical composition, which may occur with disease processes.
Although MRS is primarily employed as a research tool and has yet to achieve widespread acceptance in routine clinical practice, there is a growing realization that a noninvasive technique, which monitors disease biochemistry can provide important new information for the clinician.
The underlying principle of MRS is that atomic nuclei are surrounded by a cloud of electrons, which very slightly shield the nucleus from any external magnetic field. As the structure of the electron cloud is specific to an individual molecule or compound, then the magnitude of this screening effect is also a characteristic of the chemical environment of individual nuclei.
In view of the fact that the resonant frequency is proportional to the magnetic field that it experiences, it follows that the resonant frequency will be determined not only by the external applied field, but also by the small field shift generated by the electron cloud. This shift in frequency is called the chemical shift (see also Chemical Shift). It should be noted that chemical shift is a very small effect, usually expressed in ppm of the main frequency. In order to resolve the different chemical species, it is therefore necessary to achieve very high levels of homogeneity of the main magnetic field B0. Spectra from humans usually require shimming the magnet to approximately one part in 100. High resolution spectra of liquid samples demand a homogeneity of about one part in 1000.
In addition to the effects of factors such as relaxation times that can affect the NMR signal, as seen in magnetic resonance imaging, effects such as J-modulation or the transfer of magnetization after selective excitation of particular spectral lines can affect the relative strengths of spectral lines.
In the context of human MRS, two nuclei are of particular interest - H-1 and P-31. (PMRS - Proton Magnetic Resonance Spectroscopy) PMRS is mainly employed in studies of the brain where prominent peaks arise from NAA, choline containing compounds, creatine and creatine phosphate, myo-inositol and, if present, lactate; phosphorus 31 MR spectroscopy detects compounds involved in energy metabolism (creatine phosphate, adenosine triphosphate and inorganic phosphate) and certain compounds related to membrane synthesis and degradation. The frequencies of certain lines may also be affected by factors such as the local pH. It is also possible to determine intracellular pH because the inorganic phosphate peak position is pH sensitive.
If the field is uniform over the volume of the sample, "similar" nuclei will contribute a particular frequency component to the detected response signal irrespective of their individual positions in the sample. Since nuclei of different elements resonate at different frequencies, each element in the sample contributes a different frequency component. A chemical analysis can then be conducted by analyzing the MR response signal into its frequency components.

See also Spectroscopy.
spacer
 
• Related Searches:
    • Medical Imaging
    • Chemical Shift Artifact
    • Spectroscopy
    • Chemical Shift
    • Brain MRI
 
Further Reading:
  News & More:
Accuracy of Proton Magnetic Resonance Spectroscopy in Distinguishing Neoplastic From Non-neoplastic Brain Lesions
Saturday, 2 December 2023   by www.cureus.com    
MRI Resources 
Safety Products - Claustrophobia - MRA - Pacemaker - Liver Imaging - Shoulder MRI
 
Magnevist®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Magnevist® is a paramagnetic ionic contrast agent for use in magnetic resonance imaging. Contrast enhanced MRI with Magnevist® allows additional diagnostic information of tumors, inflammation and vascular lesions and the determination or differentiation of such lesions.
The contrast enhancing effect is produced by the di-N-methylglucamine salt of gadopentetate (Gd-DTPA), the gadolinium complex of diethylenetriamine pentaacetic acid. Magnevist® has the strongest effect on T1 weighted images, by increasing T1 signal intensity in tissues where Magnevist® has accumulated.

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.

See also Ionic Intravenous Contrast Agents and Gadopentetate Dimeglumine.
Drug Information and Specification
CENTRAL MOIETY
Gd3+
CONTRAST EFFECT
T1, Predominantly positive enhancement
r1=3.4, r2=3.8, B0=1.0T
PHARMACOKINETIC
Intravascular, extracellular, renal excretion
1960 mosm/kgH2O
CONCENTRATION
0.5 mol/L
DOSAGE
0.1-0.3 mmol/kg / 0.2-0.6 mL/kg
PREPARATION
Finished product
INDICATION
Neuro/whole body
DEVELOPMENT STAGE
For sale
DISTRIBUTOR
See below
PRESENTATION
Vials of 5, 10, 15, 20 and 100 mL bulk package
Pre-filled syringes of 10, 15 and 20 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
USA, Canada
Magnevist®
for sale
Asia
Magnevist®
for sale
EU
Magnevist®
suspended
Turkey
Magnevist®, Magnograf
for sale
Australia
Magnevist®
for sale
spacer

• View the DATABASE results for 'Magnevist®' (7).Open this link in a new window

 
Further Reading:
  Basics:
Magnevist Prescription Drug Discount Sources
   by www.institutedc.org    
Important Drug Warning for Gadolinium-Based Contrast Agents
Wednesday, 12 September 2007   by www.ismrm.org    
MAGNEVIST ® (brand of gadopentetate dimeglumine) Injection - WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
May 2009   by berlex.bayerhealthcare.com    
Magnevist Package Insert
2000
  News & More:
EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans
Friday, 21 July 2017   by www.ema.europa.eu    
Gadolinium-containing contrast agents: removal of Omniscan and iv Magnevist, restrictions to the use of other linear agents
Friday, 5 January 2018   by www.gov.uk    
FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings
Tuesday, 19 December 2017   by www.fda.gov    
Spurious Hypocalcemia After Omniscan- or OptiMARK-Enhanced Magnetic Resonance Imaging: An Algorithm for Minimizing a False-Positive Laboratory Value
October 2004   by www.findarticles.com    
MRI Resources 
Directories - MR Guided Interventions - PACS - Cochlear Implant - MRI Training Courses - MRI Accidents
 
Manganese HydroxylapatiteInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Short name: PEG-APD (MnHA/PEG-APD), generic name: Manganese substituted hydroxylapatite, central moiety: Mn2+, relaxivity: r1=21.7, r2=26.9, B0=1.0 T
An intravascular MRI contrast agent under development (preclin.) for MR angiography.
spacer
Searchterm 'B0' was also found in the following services: 
spacer
News  (1)  Forum  (4)  
 
Monocrystalline Iron Oxide NanoparticleInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
Short name: MION, central moiety: Fe3+/Fe2+, relaxivity: r1=3.7, r2=6.5, B0=0.47T
MIONs are under development (preclin.) as contrast agents (taken up by the RES) for MR angiography, MR lymphography, tumor detection and detection of infarctioned tissue. Also called monodisperse iron oxide nanoparticles or nanocompounds.
spacer

• View the DATABASE results for 'Monocrystalline Iron Oxide Nanoparticle' (3).Open this link in a new window

 
Further Reading:
  Basics:
Biomedical scientist to test nanoparticles as early cancer detection agent
Monday, 28 October 2002
  News & More:
Turning up the heat on cancer
Thursday, 22 November 2007   by www.rsc.org    
Vascular Filters of Functional MRI: Spatial Localization Using BOLD and CBV Contrast
MRI Resources 
Cardiovascular Imaging - MRA - MR Guided Interventions - Directories - Guidance - Services and Supplies
 
MultiHance®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
MultiHance® is a paramagnetic contrast agent for use in diagnostic magnetic resonance imaging (MRI) of the liver and central nervous system. MultiHance® is a small molecular weight chelate, which tightly binds the Gd atom. The substance is excreted partly by the kidneys, partly by the biliary system, which is especially unique.
MultiHance® is indicated, for the detection of focal liver lesions in patients with known or suspected primary liver cancer (e.g. hepatocellular carcinoma) or metastatic disease.
MultiHance® is also indicated in brain MRI and spine MRI where it improves the detection of lesions and provides diagnostic information additional to that obtained with unenhanced MRI.
Gd-BOPTA-enhanced MRA can provide superior vascular signal intensity and SNR, as compared with Gd-DTPA, due to its higher relaxivity, even at lower doses.
1 ml of solution MultiHance® contains: (0.5M) gadobenate dimeglumine 529 mg = gadobenic acid 334 mg + meglumine 195 mg. Viscosity at 37°C: 5.3 mPa

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
Drug Information and Specification
NAME OF COMPOUND
Gadobenate dimeglumine, Gd-BOPTA, E7155
DEVELOPER
CENTRAL MOIETY
Gd2+
CONTRAST EFFECT
T1, predominantly positive enhancement
r1=9.7, r2=12.5, B0=0.5 T
PHARMACOKINETIC
Extracellular, hepatobiliary
1970 mosm/kg
CONCENTRATION
334 mg/ml
DOSAGE
0.05 mmol/kg for Liver MRI
0.1 mmol/kg for CNS MRI
PREPARATION
Solution for injection
INDICATION
CNS, Liver MRI
DEVELOPMENT STAGE
For sale
DISTRIBUTOR
See below
PRESENTATION
Vials of 5, 10, 15 and 20 mL, 50 and 100 mL Multipacks (Pharmacy Bulk Package)
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
EU
MultiHance®
for sale
USA
MultiHance®
for sale
Australia
MultiHance®
for sale
spacer

• View the DATABASE results for 'MultiHance®' (9).Open this link in a new window


• View the NEWS results for 'MultiHance®' (1).Open this link in a new window.
 
Further Reading:
  Basics:
Important Drug Warning for Gadolinium-Based Contrast Agents
Wednesday, 12 September 2007   by www.ismrm.org    
MultiHance Package Insert(.pdf)
   by www.fda.gov    
  News & More:
FDA Expands Pediatric Age Range for MultiHance Contrast Agent
Tuesday, 30 January 2018   by www.empr.com    
MAGNETIC RESONANCE IMAGING OF FOCAL LIVER LESIONS(.pdf)
2002
BRACCO DIAGNOSTICS' MULTIHANCE EARNS FDA APPROVAL
Wednesday, 24 November 2004   by salesandmarketingnetwork.com    
MRI Resources 
MRI Physics - Education pool - Case Studies - Stent - Nerve Stimulator - Hospitals
 
previous      26 - 30 (of 44)     next
Result Pages : [1]  [2 3 4 5 6 7 8 9]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?    



Personalized protocols (age, gender, body habitus, etc.) lead to :
more automated planning 
improved patient comfort 
better diagnostics 
optimized image quality 
nothing 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • Medical-Ultrasound-Imaging • 
Copyright © 2003 - 2024 SoftWays. All rights reserved. [ 21 November 2024]
Terms of Use | Privacy Policy | Advertising
 [last update: 2024-02-26 03:41:00]